Logo

Piper Jaffray

Fulgent Genetics Prices $26.2M Public Stock Offering

The genetic testing firm is offering approximately 2.3 million shares at $11.25 per share and plans to use the funds for general corporate purposes.

Pacific Biosciences Stock Upgraded by Piper Jaffray

The bank believes investors are too focused on the potential of PacBio's merger with Illumina falling through rather than recent developments regarding its technology.

Fulgent Genetics to Offer $22.5M in Stock

The genetic testing firm has entered into an equity distribution agreement with Piper Jaffray to offer up to $30 million in stocks, with an initial offering of $22.5 million.

Genomic Health Upgraded to Overweight by Piper Jaffray

The investment bank cited management confidence in US and European test growth as meriting the upgrade, which was necessary to maintain a current $72 price target on the firm's stock.

Piper Jaffray Initiates Coverage of OncoCyte With Overweight Rating

An analyst said the DetermaVu test could potentially be best in class for lung cancer diagnosis and that CMS could begin reimbursing for it in late 2020.

Oct 10, 2018

Myriad Upgraded to Overweight by Piper Jaffray; Signs Lab Service Deal with Pfizer

Jul 27, 2015

Piper Jaffray Initiates Coverage of Natera with Overweight Rating

Aug 11, 2014

Piper Jaffray, Mizuho Initiate Coverage of CareDx with Bullish Outlooks

Jun 20, 2014

Piper Jaffray Initiates Coverage of Veracyte with Overweight Rating

Dec 4, 2013

Qiagen Officials Talk TB Test, GeneReader Opportunities at Piper Jaffray Conference

Sep 18, 2013

Investment Bank Upgrades BD to Overweight, Raises Price Target

Sep 18, 2013

Piper Jaffray Initiates Coverage of PerkinElmer with Overweight Rating

Sep 5, 2013

Piper Jaffray Upgrades BioMérieux on Plans to Buy BioFire

Aug 2, 2013

Piper Jaffray Upgrades PacBio Following Earnings Results

Jul 19, 2013

Piper Jaffray Upgrades Cepheid; Other Analysts More Cautious

Jul 17, 2013

Piper Jaffray Downgrades Hologic, Citing Competition from Roche's HPV Business

Jul 2, 2013

Piper Jaffray Downgrades Illumina Stock

Mar 1, 2013

Piper Jaffray Upgrades Sequenom to Overweight

Jan 4, 2013

Piper Jaffray Downgrades Cepheid on Lingering Manufacturing Issues

Oct 9, 2012

Analysts, Investors 'Troubled' as Affymetrix's Preliminary Q3 Revenues Miss Estimates
Premium

Oct 9, 2012

Piper Jaffray Upbeat on MiSeq; Dismisses Rumors of Roche-Illumina Deal

Oct 4, 2012

Piper Jaffray Initiates Coverage of Quidel with Overweight Rating, Noting Firm's MDx Shift

Sep 24, 2012

Piper Jaffray Downgrades Sequenom Stock

Sep 13, 2011

Piper Jaffray Initiates Coverage of Meridian Bioscience with Underweight Rating

Jun 24, 2011

Piper Jaffray Raises Price Target on Cepheid Stock

Breaking News
The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.